Stephen Chia
BCCA - Vancouver Cancer Centre · BCCA - Vancouver Cancer Centre, BC Canada · BCCA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephen Chia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05601440 · Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerCanadian Cancer Trials Group · recruiting · Breast Cancer · study chair
- Ph3NCT04650581 · Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase InhibitorCanadian Cancer Trials Group · active not recruiting · Breast Cancer · study chair
- N/ANCT03790813 · Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast CancersBritish Columbia Cancer Agency · unknown · Breast Cancer · principal investigator
- Ph1NCT02649686 · Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving TrastuzumabCanadian Cancer Trials Group · completed · Metastatic Breast Cancer · study chair
- Ph2NCT01814865 · Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast CancerBritish Columbia Cancer Agency · withdrawn · Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer · principal investigator
- Ph1/Ph2NCT01138384 · Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast CancerNCIC Clinical Trials Group · completed · Breast Cancer · study chair
- N/ANCT00816582 · PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast CancerBritish Columbia Cancer Agency · terminated · Breast Cancer · principal investigator
- Ph1NCT00627835 · Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)British Columbia Cancer Agency · withdrawn · Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) · principal investigator
- Ph2NCT00258375 · OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast CancerNCIC Clinical Trials Group · completed · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- 18F-Fluoroestradiol PET/CT guided fulvestrant therapy for patients with recurrentR21CA139814 · NCI · BRITISH COLUMBIA CANCER AGENCY · fiscal years 2009 to 2010 · $236,417 awarded in 2010Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:14 UTC. The ranking covers the 200 most relevant of 102 PubMed records, and a shared surname and initials can bring in a namesake. All 102 on PubMed
- 977 citationsRCR 27.3
- 909 citationsRCR 29.7
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med · 2021778 citationsRCR 43.5
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.N Engl J Med · 2020673 citationsRCR 28.4
- 465 citationsRCR 13.9
- 441 citationsRCR 13.0
- 432 citationsRCR 12.6
- 391 citationsRCR 8.3
- Ribociclib plus Endocrine Therapy in Early Breast Cancer.N Engl J Med · 2024377 citationsRCR 46.5
- 281 citationsRCR 13.6